Relay Therapeutics, Inc. Common Stock

RLAYNASDAQUSD
18.56 USD
0.73 (4.09%)AT CLOSE (11:59 AM EDT)
18.67
0.11 (0.59%)
POST MARKET (AS OF 07:58 PM EDT)
Post Market
AS OF 07:58 PM EDT
18.67
0.11 (0.59%)
🔴Market: CLOSED

Relay Therapeutics, Inc. Common Stock (RLAY) trades at $18.56 per share. There is a divergence between signals — technical indicators rate "Strong Buy" but underlying fundamentals lean "Sell". Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 1/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Furthermore, RLAY is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of Jun 26, 2026.

Open?$17.62
High?$18.76
Low?$17.62
Prev. Close?$17.83
Volume?12.6M
Avg. Volume?5.2M
VWAP?$18.38
Rel. Volume?2.42x
Bid / Ask
Bid?$18.52 × 100
Ask?$19.00 × 100
Spread?$0.48
Midpoint?$18.76
Valuation & Ratios
Market Cap?4.0B
Shares Out?191.6M
Float?116.7M
Float %?65.3%
P/E Ratio?N/A
P/B Ratio?6.30
EPS?-$1.25
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
Employees
192
Market Cap
3.9B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2020-07-16
Address
60 HAMPSHIRE STREET
CAMBRIDGE, MA 02139
Phone: 617-370-8837
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bullish(+2/3)
Medium-Term (Wave)? Bullish(+3/3)
Short-Term (Ripple)? Bullish(+2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
100
Momentum?
25
Short Sent.?
11
Piotroski F-Score?1/9Weak
Altman Z-Score?37.78Safe
Confidence?55%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?32.67%Squeeze Risk
Short Interest?38.1M
Days to Cover?9.9
Free Float116.7M
Avg Daily Volume3.9M
Settlement Date2026-06-15
Financial Health
Current Ratio?22.13Strong
Quick Ratio?22.13Strong
Cash Ratio?6.88Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A
P/B?
Peers
100
S&P
29
6.30FAIR
P/S?
Peers
100
S&P
3
378.85HIGH
P/FCF?
N/A
EV/EBITDA?
S&P
97
-13.1CHEAP
EV/Sales?
Peers
100
S&P
3
359.69HIGH
Returns & Efficiency
ROE?
S&P
3
-42.5%WEAK
ROA?
S&P
3
-39.0%WEAK
Cash Flow & Enterprise
FCF?$-213383000
Enterprise Value?$3.8B
Fundamentals ratios updated end of day